New Jersey S4089 mandates health insurance carriers to cover genetic testing after a pancreatic cancer diagnosis.
New Jersey S4089 requires health insurance carriers to cover genetic testing after a diagnosis of pancreatic cancer. This includes various types of genetic tests such as germline testing and tumor molecular profiling. The bill applies to all health benefits plans and contracts in New Jersey, ensuring that the benefits for genetic testing are provided to the same extent as for any other medical condition. The provisions of this act will take effect on the first day of the fourth month following the date of enactment.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.